The global Wilson disease drugs market accounted for $595.17 million in 2021, and is expected to reach $848.19 million by 2031, registering a CAGR of 3.6% from 2022 to 2031.
Wilson disease is a rare inherited disorder that causes copper to accumulate in the liver, brain and other vital organs of human body. most people with Wilson's disease are diagnosed between the ages of 5 and 35, but it can affect younger and older people, as well. Copper plays a key role in the development of healthy nerves, bones, collagen and the skin pigment melanin. It is normally absorbed from food, and excess is excreted through a substance produced in liver (bile). However, in people with Wilson's disease, copper is not eliminated properly and instead accumulates, possibly to a life-threatening level. Wilson's disease is treatable when diagnosed early, and many people with the disorder live normal lives.
Wilson's disease is inherited as an autosomal recessive trait, this indicates that a person must inherit one copy of the defective gene from each parent in order to have the disease. If the person receives only one abnormal gene, he may not become ill himself, but he is a carrier and can pass the gene to children. Untreated Wilson's disease can be fatal. Serious complications include scaring of liver, kidney problems, liver failure, persistent neurological problems, psychological problems, and blood problems. Wilson disease drugs market is expected to experience significant market growth during the forecast period owing to increase in the prevalence of Wilson disease, advancement in R&D activities for drug development, and rise in adoption of early diagnosis. In addition, increase in investment by players in R&D and presence of robust pipeline candidates, rise in expenditure on the development of healthcare infrastructure, increase in public awareness about the disease prevention in developing regions, and surge in demand for personalized medicine which further facilitate the growth of the market. However, lack of awareness and diagnosis facility associated with Wilson disease treatment and high treatment cost due to complications are expected to impede the market growth. In contrast, high investment by the government for drug development and increase in healthcare expenditure are factors that present new pathway in the industry are anticipated to provide significant growth opportunities for the Wilson disease drugs market.
The Wilson disease drugs market is segmented on the basis of drug type, distribution channel and region. Depending on drug type, the market is classified into Penicillamine, Trientine and Zinc. By distribution channel, the market is classified into hospital pharmacy, retail pharmacy, and online pharmacy. Region wise, the market is analyzed across North America (the U. S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The report provides a comprehensive analysis of the key players that operate in the global Wilson disease drugs market. The key companies profiled in the report include ANI Pharmaceuticals, Inc., APOTEX, Bausch Health Companies Inc., Breckenridge Pharmaceutical, Inc., Dr. Reddy's Laboratories Ltd, Lupin Limited, NAVINTA LLC, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Vivet Therapeutics
Wilson disease is a rare inherited disorder that causes copper to accumulate in the liver, brain and other vital organs of human body. most people with Wilson's disease are diagnosed between the ages of 5 and 35, but it can affect younger and older people, as well. Copper plays a key role in the development of healthy nerves, bones, collagen and the skin pigment melanin. It is normally absorbed from food, and excess is excreted through a substance produced in liver (bile). However, in people with Wilson's disease, copper is not eliminated properly and instead accumulates, possibly to a life-threatening level. Wilson's disease is treatable when diagnosed early, and many people with the disorder live normal lives.
Wilson's disease is inherited as an autosomal recessive trait, this indicates that a person must inherit one copy of the defective gene from each parent in order to have the disease. If the person receives only one abnormal gene, he may not become ill himself, but he is a carrier and can pass the gene to children. Untreated Wilson's disease can be fatal. Serious complications include scaring of liver, kidney problems, liver failure, persistent neurological problems, psychological problems, and blood problems. Wilson disease drugs market is expected to experience significant market growth during the forecast period owing to increase in the prevalence of Wilson disease, advancement in R&D activities for drug development, and rise in adoption of early diagnosis. In addition, increase in investment by players in R&D and presence of robust pipeline candidates, rise in expenditure on the development of healthcare infrastructure, increase in public awareness about the disease prevention in developing regions, and surge in demand for personalized medicine which further facilitate the growth of the market. However, lack of awareness and diagnosis facility associated with Wilson disease treatment and high treatment cost due to complications are expected to impede the market growth. In contrast, high investment by the government for drug development and increase in healthcare expenditure are factors that present new pathway in the industry are anticipated to provide significant growth opportunities for the Wilson disease drugs market.
The Wilson disease drugs market is segmented on the basis of drug type, distribution channel and region. Depending on drug type, the market is classified into Penicillamine, Trientine and Zinc. By distribution channel, the market is classified into hospital pharmacy, retail pharmacy, and online pharmacy. Region wise, the market is analyzed across North America (the U. S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The report provides a comprehensive analysis of the key players that operate in the global Wilson disease drugs market. The key companies profiled in the report include ANI Pharmaceuticals, Inc., APOTEX, Bausch Health Companies Inc., Breckenridge Pharmaceutical, Inc., Dr. Reddy's Laboratories Ltd, Lupin Limited, NAVINTA LLC, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Vivet Therapeutics
KEY BENEFITS FOR STAKEHOLDERS
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the wilson disease drugs market analysis from 2021 to 2031 to identify the prevailing wilson disease drugs market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the wilson disease drugs market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global wilson disease drugs market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Drug Type
- Trientine
- Zinc
- Penicillamine
By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
By Region
- North America
- U. S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- Apotex
- ANI Pharmaceuticals Inc
- Teva Pharmaceutical Industries Limited
- Lupin Ltd
- Dr. Reddy's Laboratories Ltd
- Bausch Health Companies Inc.
- Panacea Biotec Ltd
- par pharmaceutical
- navinta llc
- breckenridge pharmaceutical, inc.
Table of Contents
CHAPTER 1: INTRODUCTION1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: WILSON DISEASE DRUGS MARKET, BY DRUG TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Penicillamine
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market share analysis by country
4.3 Trientine
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market share analysis by country
4.4 Zinc
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market share analysis by country
CHAPTER 5: WILSON DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL
5.1 Overview
5.1.1 Market size and forecast
5.2 Retail Pharmacies
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market share analysis by country
5.3 Hospital Pharmacies
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market share analysis by country
5.4 Online Pharmacies
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market share analysis by country
CHAPTER 6: WILSON DISEASE DRUGS MARKET, BY REGION
6.1 Overview
6.1.1 Market size and forecast
6.2 North America
6.2.1 Key trends and opportunities
6.2.2 North America Market size and forecast, by Drug Type
6.2.3 North America Market size and forecast, by Distribution Channel
6.2.4 North America Market size and forecast, by country
6.2.4.1 U. S.
6.2.4.1.1 Key market trends, growth factors and opportunities
6.2.4.1.2 Market size and forecast, by Drug Type
6.2.4.1.3 Market size and forecast, by Distribution Channel
6.2.4.2 Canada
6.2.4.2.1 Key market trends, growth factors and opportunities
6.2.4.2.2 Market size and forecast, by Drug Type
6.2.4.2.3 Market size and forecast, by Distribution Channel
6.2.4.3 Mexico
6.2.4.3.1 Key market trends, growth factors and opportunities
6.2.4.3.2 Market size and forecast, by Drug Type
6.2.4.3.3 Market size and forecast, by Distribution Channel
6.3 Europe
6.3.1 Key trends and opportunities
6.3.2 Europe Market size and forecast, by Drug Type
6.3.3 Europe Market size and forecast, by Distribution Channel
6.3.4 Europe Market size and forecast, by country
6.3.4.1 Germany
6.3.4.1.1 Key market trends, growth factors and opportunities
6.3.4.1.2 Market size and forecast, by Drug Type
6.3.4.1.3 Market size and forecast, by Distribution Channel
6.3.4.2 France
6.3.4.2.1 Key market trends, growth factors and opportunities
6.3.4.2.2 Market size and forecast, by Drug Type
6.3.4.2.3 Market size and forecast, by Distribution Channel
6.3.4.3 UK
6.3.4.3.1 Key market trends, growth factors and opportunities
6.3.4.3.2 Market size and forecast, by Drug Type
6.3.4.3.3 Market size and forecast, by Distribution Channel
6.3.4.4 Italy
6.3.4.4.1 Key market trends, growth factors and opportunities
6.3.4.4.2 Market size and forecast, by Drug Type
6.3.4.4.3 Market size and forecast, by Distribution Channel
6.3.4.5 Spain
6.3.4.5.1 Key market trends, growth factors and opportunities
6.3.4.5.2 Market size and forecast, by Drug Type
6.3.4.5.3 Market size and forecast, by Distribution Channel
6.3.4.6 Rest of Europe
6.3.4.6.1 Key market trends, growth factors and opportunities
6.3.4.6.2 Market size and forecast, by Drug Type
6.3.4.6.3 Market size and forecast, by Distribution Channel
6.4 Asia-Pacific
6.4.1 Key trends and opportunities
6.4.2 Asia-Pacific Market size and forecast, by Drug Type
6.4.3 Asia-Pacific Market size and forecast, by Distribution Channel
6.4.4 Asia-Pacific Market size and forecast, by country
6.4.4.1 China
6.4.4.1.1 Key market trends, growth factors and opportunities
6.4.4.1.2 Market size and forecast, by Drug Type
6.4.4.1.3 Market size and forecast, by Distribution Channel
6.4.4.2 Japan
6.4.4.2.1 Key market trends, growth factors and opportunities
6.4.4.2.2 Market size and forecast, by Drug Type
6.4.4.2.3 Market size and forecast, by Distribution Channel
6.4.4.3 India
6.4.4.3.1 Key market trends, growth factors and opportunities
6.4.4.3.2 Market size and forecast, by Drug Type
6.4.4.3.3 Market size and forecast, by Distribution Channel
6.4.4.4 South Korea
6.4.4.4.1 Key market trends, growth factors and opportunities
6.4.4.4.2 Market size and forecast, by Drug Type
6.4.4.4.3 Market size and forecast, by Distribution Channel
6.4.4.5 Australia
6.4.4.5.1 Key market trends, growth factors and opportunities
6.4.4.5.2 Market size and forecast, by Drug Type
6.4.4.5.3 Market size and forecast, by Distribution Channel
6.4.4.6 Rest of Asia-Pacific
6.4.4.6.1 Key market trends, growth factors and opportunities
6.4.4.6.2 Market size and forecast, by Drug Type
6.4.4.6.3 Market size and forecast, by Distribution Channel
6.5 LAMEA
6.5.1 Key trends and opportunities
6.5.2 LAMEA Market size and forecast, by Drug Type
6.5.3 LAMEA Market size and forecast, by Distribution Channel
6.5.4 LAMEA Market size and forecast, by country
6.5.4.1 Brazil
6.5.4.1.1 Key market trends, growth factors and opportunities
6.5.4.1.2 Market size and forecast, by Drug Type
6.5.4.1.3 Market size and forecast, by Distribution Channel
6.5.4.2 Saudi Arabia
6.5.4.2.1 Key market trends, growth factors and opportunities
6.5.4.2.2 Market size and forecast, by Drug Type
6.5.4.2.3 Market size and forecast, by Distribution Channel
6.5.4.3 South Africa
6.5.4.3.1 Key market trends, growth factors and opportunities
6.5.4.3.2 Market size and forecast, by Drug Type
6.5.4.3.3 Market size and forecast, by Distribution Channel
6.5.4.4 Rest of LAMEA
6.5.4.4.1 Key market trends, growth factors and opportunities
6.5.4.4.2 Market size and forecast, by Drug Type
6.5.4.4.3 Market size and forecast, by Distribution Channel
CHAPTER 7: COMPANY LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Players
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.5. Top player positioning, 2021
CHAPTER 8: COMPANY PROFILES
8.1 Apotex
8.1.1 Company overview
8.1.2 Key Executives
8.1.3 Company snapshot
8.1.4 Operating business segments
8.1.5 Product portfolio
8.1.6 Business performance
8.1.7 Key strategic moves and developments
8.2 ANI Pharmaceuticals Inc
8.2.1 Company overview
8.2.2 Key Executives
8.2.3 Company snapshot
8.2.4 Operating business segments
8.2.5 Product portfolio
8.2.6 Business performance
8.2.7 Key strategic moves and developments
8.3 Teva Pharmaceutical Industries Limited
8.3.1 Company overview
8.3.2 Key Executives
8.3.3 Company snapshot
8.3.4 Operating business segments
8.3.5 Product portfolio
8.3.6 Business performance
8.3.7 Key strategic moves and developments
8.4 Lupin Ltd
8.4.1 Company overview
8.4.2 Key Executives
8.4.3 Company snapshot
8.4.4 Operating business segments
8.4.5 Product portfolio
8.4.6 Business performance
8.4.7 Key strategic moves and developments
8.5 Dr. Reddy's Laboratories Ltd
8.5.1 Company overview
8.5.2 Key Executives
8.5.3 Company snapshot
8.5.4 Operating business segments
8.5.5 Product portfolio
8.5.6 Business performance
8.5.7 Key strategic moves and developments
8.6 Bausch Health Companies Inc.
8.6.1 Company overview
8.6.2 Key Executives
8.6.3 Company snapshot
8.6.4 Operating business segments
8.6.5 Product portfolio
8.6.6 Business performance
8.6.7 Key strategic moves and developments
8.7 Panacea Biotec Ltd
8.7.1 Company overview
8.7.2 Key Executives
8.7.3 Company snapshot
8.7.4 Operating business segments
8.7.5 Product portfolio
8.7.6 Business performance
8.7.7 Key strategic moves and developments
8.8 par pharmaceutical
8.8.1 Company overview
8.8.2 Key Executives
8.8.3 Company snapshot
8.8.4 Operating business segments
8.8.5 Product portfolio
8.8.6 Business performance
8.8.7 Key strategic moves and developments
8.9 navinta llc
8.9.1 Company overview
8.9.2 Key Executives
8.9.3 Company snapshot
8.9.4 Operating business segments
8.9.5 Product portfolio
8.9.6 Business performance
8.9.7 Key strategic moves and developments
8.10 breckenridge pharmaceutical, inc.
8.10.1 Company overview
8.10.2 Key Executives
8.10.3 Company snapshot
8.10.4 Operating business segments
8.10.5 Product portfolio
8.10.6 Business performance
8.10.7 Key strategic moves and developments
Executive Summary
According to this report, titled, 'Wilson Disease Drugs Market,' the wilson disease drugs market size was valued at $595.17 million in 2021, and is estimated to reach $848.2 million by 2031, growing at a CAGR of 3.6% from 2022 to 2031.Wilson disease is an inherited disorder in which excessive amounts of copper accumulate in the body, particularly in the liver, brain, and eyes. The signs and symptoms of Wilson disease usually first appear between the ages of 5 and 38, but they most often begin during the teenage years. The features of this condition include a combination of liver disease and neurological and psychiatric problems.
Liver disease is typically the initial feature of Wilson disease in affected children and young adults; individuals diagnosed at an older age usually do not have symptoms of liver problems, although they may have very mild liver disease. The signs and symptoms of liver disease include yellowing of the skin or whites of the eyes (jaundice), fatigue, loss of appetite, and abdominal swelling.
Nervous system or psychiatric problems are often the initial features in individuals diagnosed in adulthood and commonly occur in young adults with Wilson disease. Signs and symptoms of these problems can include clumsiness, tremors, difficulty walking, speech problems, impaired thinking ability, depression, anxiety, and mood swings. In many individuals with Wilson disease, copper deposits in the front surface of the eye (The cornea) form a green-to-brownish ring, called the Kayser-Fleischer ring, that surrounds the colored part of the eye. Abnormalities in eye movements, such as a restricted ability to gaze upwards, may also occur.
The key factors that drive the growth of wilson disease drugs market size is increase in the prevalence of Wilson disease, advancement in R&D activities for drug development, and rise in adoption of early diagnosis. Moreover, increase in investmentby players in R&D and presence of robust pipeline candidates and rise in expenditure on the development of healthcare infrastructure are further expected to boost the wilson disease drugs industry growth during forecast period. However, high treatment cost due to complications is likely to hamper the growth of the Wilson disease drugs market during the forecast period. Conversely, high investment by the government for drug development and increase in healthcare expenditure are expected to provide numerous opportunities for market growth during the forecast period.
By drug type, the Penicillamine segment dominated the wilson disease drugs market share in 2021 and is expected to remain dominant during the forecast period, owing to increase in prevalence of Wilson disease. In addition, penicillamine binds to copper and helps it to be removed from the body. Decreasing copper levels helps to improve liver function and the mental/mood/nerve problems (such as confusion, difficulty speaking/walking) caused by the disease further boost the wilson disease drugs market trends.
By distribution channel, the retail pharmacies segment dominated the wilson disease drugs market share in 2021 and is expected to remain dominant during the forecast period, owing to increase in Wilson disease patients, the growing number of independent pharmacies and chains along with the availability of medications in supermarkets & mass retailers in countries, such as the U.S. and UK. In addition, the presence of large chains, such as CVS Health, Boots Walgreens, Shoppers Drug Mart, Lloyd, and Well pharmacy, in a few countries, such as the U.S., Canada, the U.K., Australia, and Russia Further propel the market growth. Moreover, the rapid adoption of automation technologies, such as pharmacy robots, dispensing, and packaging systems is driving the segment growth.
Region wise, wilson disease drugs market analysis across North America, Europe, asia-Pacific and LAMEA. North America has the highest market share, with $251.28 million in 2021, registering a CAGR of 2.2% during the forecast period. Owing to the investments made by the key players for various R&D activities as well as launch of new products in the U.S. In addition, increase awareness among the consumers for the adoption of Wilson disease drugs is further anticipated to stimulate the growth of the Wilson disease drugs industry in North America. Asia pacific is projected to register the highest CAGR of 5.5% during the wilson disease drugs market forecast period. The evolving healthcare regulatory landscape, an increase in the number of patients with Wilson diseases, and the government's emphasis on enhancing R&D capabilities for innovative drug development are the key driving factors that boost the growth of the market in the region.
Key findings of the study
- On the basis of drug type, the penicillamine segment dominated the market in 2021 and is expected to continue this trend during the forecast period.
- Depending on distribution channel, retail pharmacies segment is projected to grow at a CAGR of 2.2% during the forecast period.
- Region-wise, North America garnered the largest revenue share in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR 5.5% during the forecast period.
Companies Mentioned
- Apotex
- Ani Pharmaceuticals Inc.
- Teva Pharmaceutical Industries Limited
- Lupin Ltd.
- Dr.Reddy's Laboratories Ltd.
- Bausch Health Companies Inc.
- Panacea Biotec Ltd.
- Par Pharmaceutical
- Navinta LLC
- Breckenridge Pharmaceutical, Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 211 |
| Published | October 2022 |
| Forecast Period | 2021 - 2031 |
| Estimated Market Value ( USD | $ 595.17 million |
| Forecasted Market Value ( USD | $ 848.19 million |
| Compound Annual Growth Rate | 3.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
